双去水半乳糖醇与ICRF-159治疗既往接受过细胞毒性化疗的晚期乳腺癌患者的II期研究。 - Suppr | 超能文献

Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.

作者信息

Ahmann D L, O'Connell M J, Bisel H F, Edmonson J H, Hahn R G, Frytak S

出版信息

Cancer Treat Rep. 1977 Jan-Feb;61(1):81-2.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.双去水半乳糖醇与ICRF-159治疗既往接受过细胞毒性化疗的晚期乳腺癌患者的II期研究。

Cancer Treat Rep. 1977 Jan-Feb;61(1):81-2.

2

1,2:5,6-Dianhydrogalactitol in advanced breast cancer.1,2:5,6-二脱水半乳糖醇用于晚期乳腺癌

Cancer Treat Rep. 1978 May;62(5):841-2.

3

Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.VP-16-213与双去水半乳糖醇治疗转移性恶性黑色素瘤患者的II期研究。

Cancer Treat Rep. 1976 Nov;60(11):1681-2.

4

Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.双去水半乳糖醇与依托泊苷（VP-16-213）用于结直肠癌的II期研究。

Cancer Treat Rep. 1976 Sep;60(9):1247-50.

5

Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.

Cancer Treat Rep. 1985 Jun;69(6):713-6.

6

Phase I evaluation of dianhydrogalactitol (NSC-132313).双脱水半乳糖醇（NSC - 132313）的I期评估

Cancer Treat Rep. 1976 May;60(5):611-4.

7

Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.以每周一次的给药方案静脉注射去水卫矛醇的I期试验。

Cancer Treat Rep. 1976 Jul;60(7):895-901.

8

Phase II study of ICRF-159 in refractory metastatic breast cancer.

Cancer Treat Rep. 1979 Jan;63(1):111-4.

9

Adriamycin plus vincristine alone or with dibromodulcitol or ICRF-159 in metastatic breast cancer.

Cancer Clin Trials. 1981 Fall;4(3):253-60.

10

Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.丙脒腙（ICRF-159）用于先前接受过全身化疗的头颈部鳞状细胞癌患者的II期试验。

Cancer Treat Rep. 1982 Mar;66(3):557-8.

引用本文的文献

1

Alkylation by 1,2:5,6-dianhydrogalactitol of deoxyribonucleic acid and guanosine.1,2:5,6-二脱水半乳糖醇对脱氧核糖核酸和鸟苷的烷基化作用。

Biochem J. 1980 Mar 1;185(3):659-66. doi: 10.1042/bj1850659.

2

Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells.

Cancer Chemother Pharmacol. 1989;23(1):41-6. doi: 10.1007/BF00258456.

3

Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.两种烷化剂之间不存在交叉耐药性：卡莫司汀与双功能半乳糖醇。

Cancer Chemother Pharmacol. 1989;24(5):311-3. doi: 10.1007/BF00304764.